Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5904716 A
Publication typeGrant
Application numberUS 08/429,122
Publication dateMay 18, 1999
Filing dateApr 26, 1995
Priority dateApr 26, 1995
Fee statusPaid
Also published asDE69626560D1, DE69626560T2, EP0739631A2, EP0739631A3, EP0739631B1
Publication number08429122, 429122, US 5904716 A, US 5904716A, US-A-5904716, US5904716 A, US5904716A
InventorsEl Gendler
Original AssigneeGendler; El
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method for reconstituting cartilage tissue using demineralized bone and product thereof
US 5904716 A
Abstract
Continuous, flexible demineralized bone is used as a support for growing cartilage tissue that may be used for implantation into a patient to replace defective of missing cartilage.
Images(2)
Previous page
Next page
Claims(11)
What is claimed is:
1. A biological material comprising cartilage tissue reconstituted on a substrate in vitro from isolated chondrocytes wherein the substrate is a continuous, flexible sheet of demineralized natural bone, having a thickness less than about 1.5 mm and chondrocyte growth extends into Haversian channels of the substrate.
2. A method for producing a biological material comprising reconstituted cartilage tissue, wherein the method comprises isolating chondrocytes from cartilage tissue, contacting a substrate comprised of a continuous, flexible sheet of demineralized natural bone, having a thickness less than about 1.5 mm, with said chondrocytes, and culturing the chondrocytes on the substrate in growth media to produce a biological material characterized by a continuous layer of cartilage tissue and chondrocyte growth extends into Haversian channels of the substrate.
3. The method of claim 2 wherein the chondrocytes are isolated from human articular cartilage tissue.
4. The method of claim 3, wherein the chondrocytes are isolated by sequential enzyme digestion techniques.
5. A method for making a cartilaginous structure comprising providing a substrate comprised of a continuous, flexible sheet of demineralized natural bone, having a thickness less than about 1.5 mm, in a nutrient environment and attaching cartilage cells to the substrate to form a cartilaginous structure which covers the surface of the substrate and chondrocyte growth extends into Haversian channels of the substrate, said substrate being suitable for implantation into a patient to replace defective or missing cartilage.
6. The method of claim 5 further comprising implanting the attached cells on the substrate in an animal without first proliferating the cells on the substrate in vitro.
7. The method of claim 5 further comprising proliferating the cells on the substrate in vitro in a nutrient media, then implanting a structure comprising the expanded cells on the substrate in vitro.
8. The method of claim 7 wherein the structure is implanted to repair cartilage damaged by inflammation.
9. The method of claim 7 wherein the structure is implanted to repair cartilage damaged by trauma.
10. The method of claim 7 wherein the structure is implanted to repair cartilage damaged by aging.
11. The method of claim 7 wherein the structure is implanted to repair cartilage which is congenitally defective.
Description
FIELD OF THE INVENTION

The present invention relates to reconstituted cartilage tissue; to a method for producing reconstituted cartilage tissue by use of a biocompatible support material as a substrate for impregnation with living cells to enable cell growth and division; and to cartilage tissue reconstituted in vitro from isolated chondrocytes.

BACKGROUND OF THE INVENTION

This invention is primarily directed to reconstituted articular cartilage, which is a specialized tissue found at the end of articulating bones. Cartilage, unlike other connective tissues, lacks blood vessels, nerves lymphatics and basement membrane. It is responsible for the distribution of load resistance to compressive forces, and the smooth gliding that is part of joint function.

Cartilage is composed of chondrocytes which synthesize an abundant extracellular matrix, which is composed of water, collagens, proteoglycans and noncollagenous proteins and lipids. Collagen serves to trap proteoglycans and to provide tensile strength to the tissue.

Damage of cartilage produced by disease, such as arthritis, or trauma is a major cause of physical deformity and debilitation. In medicine today, the primary therapy for loss of cartilage is replacement with a prosthetic material, such as silicone for cosmetic repairs, or metal alloys for joint relinement. Placement of prostheses is commonly associated with significant loss of underlying tissue and bone without recovery of the full function allowed by the original cartilage, as well as the irritating presence of a foreign body. Other long term problems associated with a permanent foreign body can include infection, erosion and instability

Very little has ever been actually used to replace the cartilage overlaying bone surfaces. To date, the growth of new cartilage from either transplantation of autologous or allogeneic cartilage has been largely unsuccessful. Microscopic islands of cartilage formation have recently been demonstrated histologically in vivo by implanting recombinant bone morphogenic protein, as reported by J. M. Wozney, et al., Science, 242, 1528-1534, (Dec. 16, 1988). Limited success has been achieved in making neocartilage using free autogenous grafts of perichondrial flaps, as described by J. Upton, Plastic and Reconstructive Surgery, 68(2), 166-174; (August 1981).

It is also known in the art to use cells harvested from an organism for implantation into the same or a different organism. Such techniques are shown is U.S. Pat. Nos. 4,299,819, 4,418,691, 4,458,678, 4,505,266, 4,553,272, 4,804,382, 4,883,487, 4,904,259, 4,960,423, 5,015,584, 5,035,708, and 5,041,138 the disclosures of which are expressly incorporated herein by reference. In these references, the cells are seeded on a biocompatible support material and implanted into a desired site for tissue repair, with or without a step of cell cultivation in vitro, depending upon the type of tissue being replaced and the extent of tissue damage at the site needing repair. The limitations of his technique are associated with the substrate material. Typically, bioabsorbable substrates are used for cell seeding. During cell cultivation in vitro, portions of these substrate materials are absorbed, leaving a support material for implantation which does not have the strength and resiliency to function as a prosthetic device at the site of tissue damage while additional tissue ingrowth and cell division takes place.

The provision of a suitable support material is a critical part of the in vitro cell cultivation technique. This is because most types of tissue will not grow or divide in suspension; a solid support is necessary for the cells to perform their normal functions. However, because the growing cells must receive nutrients from the nutrient media and eliminate cell waste products, all without a circulatory system which normally performs this function, the support upon which the cells are placed must allow for this exchange. Additionally, many cell cultures require a support coated with materials which form a part of the extracellular matrix, a collection of polysaccharides and proteins which exist outside the cell's membrane.

Cheung (in vitro Cell. Dev. Biol. 21:353, 1985) teaches a method of culturing canine chondrocytes on porous hydroxyapatite ceramic granules. The cells reportedly proliferated and secreted metachromatic extracellular matrix for up to 13 months. An agarose gel matrix has also been described as suitable for the in vitro culture of human chondrocytes (Delbruck et al., Conn. Tiss. Res. 15:155, 1986). Watt and Dudhia (Differentiation 38:140, 1988) disclose a composite gel of collagen and agarose for the culture of porcine chondrocytes. The composite gel prevented chondrocytes spreading. However, virtually no extracellular matrix was secreted in the low density culture composite gels.

Macklis et al. (in vitro Cell. Develop. Biol. 21:180, 1985) teach a collagen surface for culturing peripheral nervous system cells, comprising collagen derivatized to polystyrene plastic culture dishes. Macklis et al. disclose that the derivatized coating process yielded enhanced collagen adhesion and increased long term survival of cultured nerve cells, compared to collagen coating produced by absorption techniques.

U.S. Pat. No. 5,376,118, relates to the use of a support material fabricated from semiabsorbable, composite yarn as a support for cell growth in vitro. The support comprises a nonabsorbable, elastic core yarn and at least one absorbable, relatively inelastic sheath yarn imparting transverse strength to the composite yarn. The cells that can be grown on the support allegedly encompass endothelial cells, epidermal cells, muscle cells, bone cells, and cartilage cells.

U.S. Pat. No. 5,326,357, relates to the use of a substrate for chondrocyte cell growth in vitro. The substrate that is employed is a synthetic substrate, Millicell®-CM, coated with attachment factors.

U.S. Pat. No. 5,041,138, relates to a method for making a cartilaginous structure by use of a biocompatible, biodegradable synthetic polymeric matrix for chondrocyte cell growth in vitro , and its use for replacing defective or missing cartilage.

To date, none of the aforementioned methods of cartilage growth and replacement have found wide acceptance. As can be seen from the descriptions, the methods that use chondrocyte cell growth in vitro, rely upon synthetic support media that are foreign to the body, resulting in problems associated with the introduction of foreign compositions into the body.

A need therefore exist for a method for growing chondrocytes ex vivo by use of a supportive substrate that will find universal acceptance upon implantation for reconstructive use, while providing the characteristics necessary for cell growth in vitro.

SUMMARY OF THE INVENTION

The present invention provides a method for growing chondrocytes ex vivo, by use of a supportive substrate that is uniquely biocompatible, making the resulting structure with cartilage growth thereon especially useful for implantation for reconstructive use, while the structure provides the characteristics necessary for cell growth in vitro.

In accordance with the present invention, the supportive substrate that is used for chondrocyte growth in vitro is a continuous, flexible sheet of demineralized natural bone, having a thickness less than about 1.5 mm. As used herein below, all reference to use of a substrate is meant to refer to the aforementioned flexible sheet of demineralized bone.

Use of such a substrate provides a surface with physiological orientation of collagen fibers and physiological micro-anatomy and micro-porosity. This provides chondrocytes with a physiological receptor surface for attachment and allows for good exchange of nutrients and gases approximately equivalent to that which occurs in vivo.

The surface of the substrate, which is pliable and flexible, easily adopts to the surface of exposed subchondral bone, which can be microperforated to stimulate outward migration of undifferentiated mesenchymal cells of bone marrow. Because the substrate is a membrane made from demineralized bone it is capable to act as osteoinductive agent. Thus, undifferentiated mesenchymal cells coming in contact with the substrate differentiates into cartilage and bone producing cells. Eventually the substrate, after implantation become replaced by new live bone, which unites with exposed subchondral bone and provides a physiological support for in vitro grown chondrocytes. Total replacement of the substrate in normal conditions occurs within six months after implantation.

Thus an advantage of the use of the present substrate over synthetic membranes is the physiological orientation of the resulting collagen fibers, and physiological micro-anatomy of the bone itself that is present in the substrate. This provides physiological receptor surface for attachment and proliferation of chondrocytes in vitro. Physiological micro-porosity of human bone thus provides optimal exchange of nutrients and gases.

After the implantation, the substrate demonstrates osteoinductive phenomena and instead of being resorbed by ingrowing blood vessels, becomes replaced by new live bone within six-month period. Replacement of the substrate with new live bone provides chondrocytes with physiological attachment base through which physiological exchange of nutrients and gases occurs.

Thus, the present invention also relates to a method for producing reconstituted cartilage tissue comprising removing cartilage tissue, particularly articular cartilage from the joint of an animal; digesting said cartilage tissue to obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes in growth media to produce a tissue having a biochemical composition and physiological organization substantially the same as articular cartilage tissue.

The invention further relates to artificial cartilage tissue reconstituted in vitro by digesting cartilage tissue to obtain isolated chondrocytes; forming a monolayer of chondrocytes on a substrate; culturing the chondrocytes and growth medium to produce a tissue having a biochemical composition and physiological organization substantially the same as normal mammalian cartilage tissue.

The invention still further relates to a method of using the reconstituted cartilage tissue structure of the present invention to test pharmaceutical preparations for efficacy in the treatment of diseases of the joint and to a method of using the reconstituted tissue structure of the present invention as an implant to replace or repair damaged or deficient cartilage.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows chondrocytes that have grown in vitro as multi-layer structure closely adhering to the surface of the substrate.

FIG. 2 shows chondrocyte growth that follows the contour of the substrate even in perpendicular directions. Growth of chondrocytes extends into Haversian channels which constitute a natural porosity of the substrate. This results in very tenacious attachment between new cartilage and the substrate.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As indicated above the substrate used in accordance with the present invention comprises a continuous, flexible sheet of demineralized natural bone, having a thickness less than about 1.5 mm. Such a structure is taught and can be obtained in accordance with U.S. Pat. No. 5,306,304.

There are several kinds of cartilage. Hyaline cartilage is a bluish-white, glassy translucent cartilage having a homogeneous matrix containing collagenous fibers which is found in articular cartilage, in costal cartilages, in septum of the nose, in larynx and trachea. Articular cartilage is hyaline cartilage covering the articular surfaces of bones. Costal cartilage connects the true ribs and the sternum. Fibrous cartilage contains collagen fibers. Yellow cartilage is a network of elastic fibers holding cartilage cells which is primarily found in the epiglottis, the external ear, and the auditory tube. As described below, cartilage implants can be formed of one or more types of cartilage, depending primarily on the location of the implant and the type of cartilage cells seeded onto the substrate.

In one embodiment the substrate is placed in culture media containing chondrocytes, where the chondrocytes attach to the fibers in multiple layers. Usually, the chondrocytes retain their normal rounded configuration, which appears to be useful for the chondrocytes to maintain their normal function and secrete a cartilage matrix and other bioactive molecules such as angiogenesis inhibiting factor.

The composite structure of substrate and cells can be transplanted into animals without disrupting the complex of attached chondrocytes. Transplantation of this composite containing a high density of normally functioning chondrocytes with a large surface area into an animal allows the cells to obtain adequate nutrition by diffusion and successful engraftment of functioning chondrocytes with cartilage formation even in the initial absence of vascularization.

Chondrocytes are initially isolated and cultured using techniques known to those skilled in the art of tissue culture. In contrast to some types of cells, chondrocytes can be seeded directly onto the substrate and implanted without first proliferating the cells in vitro. If insufficient cell numbers are available for implantation, cells are first cultured in vitro on the matrix. Once the cells have begun to grow and cover the matrix, they can be implanted in a patient at a site appropriate for attachment, growth and function.

Because the substrate will eventually be resorbed, angiogenic and other bioactive compounds can be incorporated directly into the substrate so that they are slowly released as the substrate degrades in vivo. As the cell-substrate composite is vascularized and the structure degrades, the cells will differentiate according to their inherent characteristics.

The reconstituted cartilage tissue of the present invention may be prepared from chondrocytes isolated from articular cartilage from animals, preferably humans. A particularly useful system may be prepared from chondrocytes isolated from human articular cartilage, for example from the kace joint. The chondrocytes may be isolated by sequential enzyme digestion techniques, such as those described in Kandel et al., Biochem. Biophys. Acta. 1035:130, 1990. For example, the cartilage may be treated with 0.5% protease followed by 0.04% bacterial collagenase.

The living cells contact an exterior portion of the substrate. Usually, the cells will be cultured in vitro on the substrate. The support material and living cells may then placed in contact with living tissue to function as a tissue repair device.

The chondrocytes seeded on the coated substrate, may be grown in suitable culture conditions. Broadly, in vitro cell cultivation involves harvesting the desired cells from the host organism, placing them on the substrate, and providing an appropriate nutrient medium and temperature and atmospheric conditions to allow the cells to grow and divide. In general, the nutrient medium contains amino acids, vitamins, salts, glucose and antibiotics. The support material impregnated with cells is placed in a suitable container in communication with the appropriate nutrient medium and maintained in an incubator until the desired number of cell divisions have occurred.

Examples of suitable culture media are known in the art, such as Ham's F12 medium. The culture medium may contain serum, for example fetal bovine serum in a concentration range of about 2-15% and may further contain growth factors and ascorbic acid. The cells may be cultured at 37° C. in a humidified atmosphere supplemented with CO2, for at least 2 weeks.

The cells, after harvest from an organism, either as an intact tissue structure or as a suspension formed, e.g., by centrifugation or ultrasonic tissue disruption, are placed in contact with a support material. Exemplary techniques for forming cell suspensions are described in U.S. Pat. Nos. 4,418,691, 4,458,678, 4,505,266, and 5,041,138.

Following formation of a suspension, the support material must be impregnated with the cells such that the cells are located on the surfaces of the various individual fibers. This impregnation may be accomplished in a variety of ways depending upon the shape and thickness of the support material. For example, the support material of the present invention may be impregnated by immersion in a cell suspension, spraying with a cell suspension, injection with a cell suspension via hypodermic needle, centrifugation of the support material with a cell suspension or any other technique in the art for impregnating a material with a suspension. Usually, the impregnation step accomplished so that the cells are placed not merely on the surface of an prosthetic implant, but are located throughout the material, adhering to the surface of the support material. The ability to situate cells on the substrate permits a higher density of cells within a given implant. As a result, faster rates of tissue formation throughout the device as well as enhanced tissue ingrowth rates and vascularization following implantation of a seeded device into the host organism are achieved.

It is within the scope of this invention to coat or impregnate the support material with, or otherwise apply thereto, one or more materials which enhance its functionality, e.g., surgically useful substances, such as those which accelerate or beneficially modify the healing process when the support material is applied to a graft site. Additionally, components of the extracellular matrix, e.g., polysaccharides and proteins such as collagen, can be coated onto the prosthetic support material of the invention to enhance cell growth and division.

As indicated, the reconstituted cartilage tissue of the present invention also can be used as a model system for in vitro studies of cartilage structure, function and development. In particular, the reconstituted cartilage of the present invention may be used in the testing of pharmaceutical preparations useful in the treatment of diseases of the joint, for example osteoarthritis, inflammatory arthropathies, septic arthritis and crystalline arthropathies.

The reconstituted cartilage tissue of the invention is principally used as an implant for use in the joints of patients to replace or repair damaged or deficient cartilage.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4299819 *Sep 13, 1979Nov 10, 1981Sloan-Kettering Institute For Cancer ResearchGrowth of epidermal cells in tissue culture
US4418691 *Oct 26, 1981Dec 6, 1983Massachusetts Institute Of TechnologyMethod of promoting the regeneration of tissue at a wound
US4458678 *Oct 26, 1981Jul 10, 1984Massachusetts Institute Of TechnologyMethod of promoting tissue generation at a wound
US4505266 *Apr 17, 1984Mar 19, 1985Massachusetts Institute Of TechnologyMethod of using a fibrous lattice
US4553272 *Feb 26, 1981Nov 19, 1985University Of PittsburghRegeneration of living tissues by growth of isolated cells in porous implant and product thereof
US4627853 *May 29, 1985Dec 9, 1986American Hospital Supply CorporationMethod of producing prostheses for replacement of articular cartilage and prostheses so produced
US4681763 *Jun 11, 1985Jul 21, 1987University Of Medicine And Dentistry Of New JerseyGuanidine hydrochloride
US4804382 *May 19, 1987Feb 14, 1989Sulzer Brothers LimitedArtificial vessel
US4883487 *Apr 6, 1987Nov 28, 1989Koken Co., Ltd.Method of producing an artifical skin
US4904259 *Dec 5, 1988Feb 27, 1990Samuel ItayExcising damaged tissue and filling with cultured implant capable of regenerating skeletal tissue
US4932973 *Apr 21, 1988Jun 12, 1990El GendlerCartilage and bone induction by artificially perforated organic bone matrix
US4960423 *Nov 17, 1982Oct 2, 1990Smith Donald WMethod of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics
US5015584 *Feb 9, 1988May 14, 1991Board Of Regents, The University Of Texas SystemCulture of skin cells, attaching cells to a collagen coated surgical dressing immersed in a eucaryotic cell culture medium to produce a composite
US5035708 *May 24, 1989Jul 30, 1991Thomas Jefferson UniversityEndothelial cell procurement and deposition kit
US5041138 *Apr 17, 1989Aug 20, 1991Massachusetts Institute Of TechnologyNeomorphogenesis of cartilage in vivo from cell culture
US5131907 *Mar 6, 1991Jul 21, 1992Thomas Jefferson UniversityMethod of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself
US5236456 *Jan 17, 1991Aug 17, 1993Osteotech, Inc.Osteogenic composition and implant containing same
US5306304 *Jan 13, 1993Apr 26, 1994El GendlerFlexible membranes produced from organic bone matrix for skeletal repair and reconstruction
US5326357 *Mar 18, 1992Jul 5, 1994Mount Sinai Hospital CorporationReconstituted cartridge tissue
US5376118 *Mar 26, 1993Dec 27, 1994United States Surgical CorporationSupport material for cell impregnation
EP0046039A1 *Jul 31, 1981Feb 17, 1982G.D. Searle & Co.Synthetic urogastrone gene, corresponding plasmid recombinants, transformed cells, production thereof and urogastrone expression
EP0128733A1 *Jun 5, 1984Dec 19, 1984Genentech, Inc.Human insulin-like growth factor (IGF) produced from a recombinant host, process, expression vector and recombinant host therefor, and IGF-containing pharmaceutical composition
EP0131868A1 *Jul 6, 1984Jan 23, 1985Wakunaga Seiyaku Kabushiki Kaisha(21-Leucine) human urogastrone, corresponding gene, corresponding recombinant plasmid, transformed cell and process for production thereof
EP0136490A2 *Aug 10, 1984Apr 10, 1985Amgen Inc.DNA plasmids
EP0147178A2 *Dec 19, 1984Jul 3, 1985Pfizer Inc.Expression plasmids for improved production of heterologous protein in bacteria
EP0150572A1 *Oct 31, 1984Aug 7, 1985AmgenMicrobial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides
EP0177915A2 *Oct 5, 1985Apr 16, 1986Takeda Chemical Industries, Ltd.Novel DNA, production and use thereof
EP0267015A2 *Nov 4, 1987May 11, 1988Ethicon Inc.Stabilized compositions containing epidermal growth factor
GB2092155A * Title not available
GB2162851A * Title not available
GB2172890A * Title not available
WO1983004030A1 *May 2, 1983Nov 24, 1983Applied Molecular Genetics IncThe manufacture and expression of genes for urogastrone and polypeptide analogs thereof
WO1985000369A1 *Jul 2, 1984Jan 31, 1985Chiron CorpHybrid dna synthesis of epidermal growth factor
WO1985001284A1 *Sep 14, 1984Mar 28, 1985Akira KomoriyaSynthetic peptides with egf like activity and pharmaceutical compositions and methods of use
WO1986002271A1 *Oct 16, 1985Apr 24, 1986Chiron CorpPromotion of wound healing with human epidermal growth factor prepared from recombinant dna
Non-Patent Citations
Reference
1 *Bettex Galand et al., Experientia, 43 (6), 610 611 (1987).
2Bettex-Galand et al., Experientia, 43 (6), 610-611 (1987).
3Buck, "Cell Surface Receptors For Extracellular Matrix Molecules", Ann. Rv. Cell Biol., 3, 179-205 (1987).
4 *Buck, Cell Surface Receptors For Extracellular Matrix Molecules , Ann. Rv. Cell Biol., 3, 179 205 (1987).
5Cheung, "In Vitro Cartilage Formation on Porous Hydroxyapatite Ceramic Granules", In Vitro Cellular & Developmental Biology, 21, 353-357, 1985.
6 *Cheung, In Vitro Cartilage Formation on Porous Hydroxyapatite Ceramic Granules , In Vitro Cellular & Developmental Biology, 21, 353 357, 1985.
7Delbruck et al., "In-Vitro Culture of Human Chondrocytes From Adult Subjects", Connective Tissue Research, 15, 155-172, 1986.
8 *Delbruck et al., In Vitro Culture of Human Chondrocytes From Adult Subjects , Connective Tissue Research, 15, 155 172, 1986.
9Macklis et al., "Cross-Linked Collagen Surface for Cell Culture That is Stable, Uniform, and . . .", In Vitro Cellular & Developmental Biology, 21, 189-194, 1985.
10 *Macklis et al., Cross Linked Collagen Surface for Cell Culture That is Stable, Uniform, and . . . , In Vitro Cellular & Developmental Biology, 21, 189 194, 1985.
11Streuli et al., "Expression of Extracellular Matrix Components Is Regulated by Substratum", Journal of Cell Biology, 110, 1405-1415 (Apr. 1990).
12 *Streuli et al., Expression of Extracellular Matrix Components Is Regulated by Substratum , Journal of Cell Biology, 110, 1405 1415 (Apr. 1990).
13Upton, "Neocartilage Derived from Transplanted Perichondrium: What is it?", Plastic and Reconstructive Surgery, 68(2), 166-174, (Aug. 1981).
14 *Upton, Neocartilage Derived from Transplanted Perichondrium: What is it , Plastic and Reconstructive Surgery, 68(2), 166 174, (Aug. 1981).
15Watt et al., "Prolonged Expression of Differentiated Phenotype by Chondrocytes Cultured at Low Density . . .", Differentiation, 38, 140-147, 1988.
16 *Watt et al., Prolonged Expression of Differentiated Phenotype by Chondrocytes Cultured at Low Density . . . , Differentiation, 38, 140 147, 1988.
17Wozney et al., "Novel Regulators of Bone Formation: Molecular Clones and Activities", Science, 242, 1528-1534, (Dec. 16, 1988).
18 *Wozney et al., Novel Regulators of Bone Formation: Molecular Clones and Activities , Science, 242, 1528 1534, (Dec. 16, 1988).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6242247 *Jun 2, 1997Jun 5, 2001Sulzer Orthopedics Ltd.Device for in vitro production includes space for receiving cells and culture medium and that has semipermeable or porous walls, and means for positioning and immersing cell space in culture medium; one wall is bone substitute plate
US6267786Feb 11, 1999Jul 31, 2001Crosscart, Inc.Proteoglycan-reduced soft tissue xenografts
US6277151 *Feb 13, 1998Aug 21, 2001Etex CorporationUsing in vivo an amorphous, hydrated calcium phospate in an aqueous solution of a paste or putty consistency; having a biocompatibility with the cartilage-forming cell or precursor; hardening
US6383732Jun 1, 2000May 7, 2002Crosscart, Inc.Method of preparing xenograft heart valves
US6387693Apr 18, 2001May 14, 2002Sulzer Orthopedics Ltd.Cells having ability to form extracellular cartilage matrix are brought into a cell space where they settle on a plate in a culture medium for producing extracellular cartilage matrix
US6455309Jun 4, 2001Sep 24, 2002Crosscart, Inc.Removing portion of soft tissue from non-human animal, washing in water and alcohol, subjecting to cellular disruption, depleting proteoglycans, whereby xenograft is nonimmunogenic and has same mechanical properties as native tissue
US6576249Nov 13, 2000Jun 10, 2003El GendlerContacting demineralized bone matrix with water at elevated temperature to aid dissolution to provide supernatant having specified viscosity, cooling to room temperature, mixing with bone matrix particles to form suspension
US6652593Aug 13, 2001Nov 25, 2003Synthes (Usa)Demineralized bone implants
US6758865May 27, 1998Jul 6, 2004Crosscart, Inc.Soft tissue xenografts
US6776800Aug 13, 2001Aug 17, 2004Synthes (U.S.A.)Implants formed with demineralized bone
US6852330Dec 21, 2000Feb 8, 2005Depuy Mitek, Inc.Bioabsorbable, porous, reinforced, biocompatible tissue repair stimulating implant for use in the repair of orthopaedic type injuries, such as damage to the meniscus and rotator cuff
US6855169Aug 13, 2001Feb 15, 2005Synthes (Usa)Demineralized bone-derived implants
US6884428Dec 16, 2002Apr 26, 2005Depuy Mitek, Inc.Biocompatible, bioabsorbable scaffold device of polymeric, open cell pore foam
US6972041Mar 15, 1999Dec 6, 2005Crosscart, Inc.Bone xenografts
US7205337Jun 19, 2003Apr 17, 2007Isotis Orthobiologics, Inc.End-capped polymers and compositions containing such compounds
US7241813Dec 20, 2002Jul 10, 2007Isotis Orthobiologics, Inc.Comprises ethylene oxide-propylene oxide copolymers; may be combined with demineralized bone particles to form tissue repair composition; bone morphogenic proteins
US7316822Nov 26, 2003Jan 8, 2008Ethicon, Inc.Injectable suspension of a tissue carrier matrix of bioresorbable granules and a tissue fragment containing viable cells that migrate from the tissue and populate the matrix; rotator cuff injuries, ACL ruptures, and meniscal tears
US7488348Jun 14, 2005Feb 10, 2009Musculoskeletal Transplant FoundationCylindrically shaped allograft structure of subchondral bone with an integral overlying smaller diameter cartilage cap which is treated to remove cellular debris and proteoglycans; dimensioned to fit in a drilled bore in a cartilage defect area; pain relief, restores normal function
US7608113Nov 24, 2003Oct 27, 2009Synthes Usa, LlcDemineralized bone implants
US7645568Aug 9, 2004Jan 12, 2010Aperion Biologics, Inc.Xenograft heart valves
US7722672Nov 8, 2002May 25, 2010Stone Kevin RBone xenografts
US7753963Sep 8, 2008Jul 13, 2010Synthes Usa, Llca unitary section of cortical bone having a first portion that is mineralized and a second portion that is at least partially demineralized; neralized portion includes a plurality of slits to facilitate bending of the unitary section; allograft; insertable into an intervertebral disk space
US7824701Feb 25, 2003Nov 2, 2010Ethicon, Inc.from monomers such as lactide, glycolide, dioxanone, and caprolactone; living cells migrate and populate scaffold; orthopedics, foot surgery
US7875296Nov 29, 2007Jan 25, 2011Depuy Mitek, Inc.Conformable tissue repair implant capable of injection delivery
US7901461Dec 5, 2003Mar 8, 2011Ethicon, Inc.Viable tissue repair implants and methods of use
US7931687May 12, 2003Apr 26, 2011Articular Engineering, LlcGrafting bone; human joints; filling defects
US8137686Apr 20, 2004Mar 20, 2012Depuy Mitek, Inc.Nonwoven tissue scaffold
US8137702Dec 29, 2010Mar 20, 2012Depuy Mitek, Inc.Conformable tissue repair implant capable of injection delivery
US8147860Dec 6, 2005Apr 3, 2012Etex CorporationPorous calcium phosphate bone material
US8216359Apr 14, 2005Jul 10, 2012Etex CorporationDelayed-setting calcium phosphate pastes
US8221780Jun 29, 2006Jul 17, 2012Depuy Mitek, Inc.Nonwoven tissue scaffold
US8221781Apr 12, 2004Jul 17, 2012Etex CorporationOsteoinductive bone material
US8226715Jun 30, 2003Jul 24, 2012Depuy Mitek, Inc.Scaffold for connective tissue repair
US8454988Jan 23, 2008Jun 4, 2013Etex CorporationOsteoinductive bone material
US8496970Feb 27, 2012Jul 30, 2013Depuy Mitek, LlcConformable tissue repair implant capable of injection delivery
US8545858Apr 3, 2012Oct 1, 2013Etex CorporationPorous calcium phosphate bone material
US8637066Sep 21, 2010Jan 28, 2014Depuy Mitek, LlcBiocompatible scaffold for ligament or tendon repair
US8641775Feb 1, 2011Feb 4, 2014Depuy Mitek, LlcViable tissue repair implants and methods of use
US8657881Apr 20, 2004Feb 25, 2014Depuy Mitek, LlcMeniscal repair scaffold
US8728536Mar 30, 2006May 20, 2014Etex CorporationChemotherapeutic composition using nanocrystalline calcium phosphate paste
US20050232967Apr 20, 2004Oct 20, 2005Kladakis Stephanie MNonwoven tissue scaffold
CN101589139BOct 31, 2006Apr 16, 2014株式会社现代组织工学Artificial cartilage containing chondrocytes obtained from costal cartilage and preparation process thereof
WO2000047131A1 *Feb 8, 2000Aug 17, 2000Crosscart IncProteoglycan-reduced soft tissue xenografts
WO2005000221A2 *May 27, 2004Jan 6, 2005Roman BarabolakEdible films including aspartame and methods of making same
WO2007052935A1 *Oct 31, 2006May 10, 2007Modern Cell & Tissue TechnologArtificial cartilage containing chondrocytes obtained from costal cartilage and preparation process thereof
Classifications
U.S. Classification424/423, 623/901, 435/372, 623/23.72, 435/366
International ClassificationA61L27/38, A61F2/30, A61K35/12, A61F2/00, C12N5/00, A61F2/28, A61L27/36, A61K38/00, C12N5/077
Cooperative ClassificationY10S623/901, A61L27/3608, C12N2533/90, C12N2503/02, A61L27/3654, A61L27/3612, A61F2/2846, A61F2310/00365, C12N5/0068, A61K38/00, C12N5/0655, A61K35/12, A61F2/30756, A61L27/38, C12N2500/38, A61F2/28, A61L27/3683
European ClassificationA61L27/36B4, A61L27/36B2, A61L27/36H, A61L27/36F2D, C12N5/06B13C, A61F2/30C, A61L27/38, C12N5/00S
Legal Events
DateCodeEventDescription
Oct 20, 2010FPAYFee payment
Year of fee payment: 12
Oct 27, 2006FPAYFee payment
Year of fee payment: 8
Aug 29, 2002FPAYFee payment
Year of fee payment: 4
Feb 19, 2002ASAssignment
Owner name: GENDLER FAMILY LIMITED PARTNERSHIP, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENDLER, EL;REEL/FRAME:012621/0854
Effective date: 20020122
Owner name: GENDLER FAMILY LIMITED PARTNERSHIP 415 GEORGINA AV
Owner name: GENDLER FAMILY LIMITED PARTNERSHIP 415 GEORGINA AV
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENDLER, EL /AR;REEL/FRAME:012621/0854